Q2
ARDX — Q2 2026 Financial Report Analysis
Ardelyx's Q2 2026 product sales rose 31% to $118.1M on 33% IBSRELA growth, and the net loss narrowed to $16.7M — though mostly because a $3.8M AstraZeneca royalty ended, while gross-to-net deductions rose to 34%.